Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that it is commencing, through a wholly owned subsidiary, Atlas Merger Sub, Inc. ("Purchaser"), a cash tender offer to
April 14, 9:14 AM
Antares Pharma Inc's (NASDAQ:ATRS) short percent of float has risen 8.8% since its last report. The company recently reported that it has 4.49 million shares sold short, which is 2.72% of all regular shares that are available for trading.
April 14, 7:54 AM
Truist Securities analyst Gregory Fraser downgrades Antares Pharma (NASDAQ:ATRS) from Buy to Hold and lowers the price target from $7 to $5.6.
April 14, 6:06 AM
HC Wainwright & Co. analyst Oren Livnat downgrades Antares Pharma (NASDAQ:ATRS) from Buy to Neutral and announces $5.6 price target.
April 14, 5:02 AM
Piper Sandler analyst David Amsellem downgrades Antares Pharma (NASDAQ:ATRS) from Overweight to Neutral and lowers the price target from $6 to $5.6.
April 13, 1:35 PM
April 13, 10:40 AM
Antares Pharma Inc (NASDAQ: ATRS) shares are trading higher Wednesday after the company announced it will be acquired by Halozyme Therapeutics Inc (NASDAQ: HALO) for $5.60 per share in cash, valuing Antares at
April 13, 6:02 AM
SAN DIEGO and EWING, N.J., April 13, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") and Antares Pharma, Inc. (NASDAQ:ATRS) ("Antares") today
Wall Street Journal Reported Halozyme Therapeutics Nears Deal to Buy Antares Pharma for $5.60/Share in Cash
April 13, 5:10 AM